Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer

Exclusion Criteria

• •Prior systemic chemotherapy for metastatic disease
• •Prior treatment with oxaliplatin or irinotecan
• •CNS metastases
• •Uncontrolled or severe cardiovascular disease
• •Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy
• •Other malignancy within the past 3 years except cured non-melanomatous skin cancer or carcinoma in situ of the cervix
• •Psychiatric disorder or uncontrolled seizure that would preclude compliance
• •Pregnant, nursing women or patients with reproductive potential without contraception
• •Patients receiving a concomitant treatment with drugs interacting with capecitabine such as flucytosine, phenytoin, or warfarin et al.
• •Prior unanticipated severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase (DPD) deficiency
• •Major surgery within 3 weeks prior to study treatment starts, or lack of complete recovery from the effects of major surgery